Inhalant 24 billion market domestic brand! 40 inhalers overrated to speed up.

Recently, the State Drug Administration issued the 29th batch of generic reference preparations catalog, of which 6 are inhalantsAccording to statistics, there are currently 40 inhalers (in terms of drug names) published reference preparations, 11 have not yet had the enterprise layout consistency evaluationMinnet data show that in 2019 China's public medical institutions terminal inhaler sales of nearly 24 billion yuan, foreign brands "bully screen", but Zhengda Qing, Hengrui and other domestic brands are rising;inhaler market sprint 24 billion, Hengrui, Zhengda Tianqing and other domestic brands rise
Figure 1: 2015-2019 China's public medical institutions terminal inhaler sales (units: 10,000 yuan)meters net data show that in recent years, China's urban public hospitals, county-level public hospitals The market for end-inhaling drugs in urban community centers and township hospitals (china's public medical institutions) has expanded year by year, with an annual growth rate of double digits, breaking the 20 billion mark for the first time in 2018 and reaching 23.68 billion yuan in 2019, up 10.51 percent year-on-yearTable 1: In 2019, China's public medical institutions terminal inhaler TOP20 brand2019 China's public medical institutions terminal inhaler TOP20 brand, 13 for foreign brands, 7 for domestic brandsAstraZeneca's dominance is hard to shake, with four products on the list, including The Inhale with Budinaide mixed suspension, Budineformotro Inhaling Powder Mist (II), which came in first and second, respectively, while Bollinger Ingehan followed with three products, one product ranking unchanged and two products fallingAlthough foreign brands still dominate the market for end-inhalers in public medical institutions in China in 2019, domestic brands have a "dominant" trend7 domestic brands year-on-year growth rate of 2018 are 2 digits and above, Hainan Star Pharmaceutical's inhalation acetylcysteine solution is as high as 899.94%, Hengrui Pharmaceutical's inhalation with heptfluororaneande and positive days of anti-bromine powder spray ranking have increased;6 inhalers reviewed, 79 inhalers in thetable 2: inhaler evaluation situation
meter net data show that there are currently 6 inhalers have been approved by enterprises through or as appropriate through the consistency evaluation, in addition to korean-American drug inhalation with hydrochloric acid brominated solution, the remaining 5 are domestic inhalers;5 of the 6 over-rated inhalants were respiratory medications, inhaled with sulphate sulfateol solution, fentanyl mixed suspension with inhalation, compound isopropyl bromine inhaling solution, hydrochloric acid L-saloxamine inhalation solution are anti-asthma drugs, inhalation of hydrochloric acid ambrominated solution for cough and cold medication;due to the high threshold of research and development of inhalation agents and technical barriers, no more than 20 domestic inhalers have been approved for listing in the past 10 years, which also determines the submission of a consistency evaluation supplement application for the few inhalersAt present, CDE contractor accepted the inhalation consistency evaluation supplementary application number only 1, for Hengrui Pharmaceuticals inhaling heptfluorane, the product in November 2015 in the United States to obtain ANDA, Hengrui in 2018 submitted a consistency evaluation supplementapplication application, in 2019 with imitation 4 class of production, the probability and Huiyu Pharmaceutical's Permequeleta in the same way approved Table 3: note on the new classification of inhalers: "not approved" for the review, has been evaluated and excluded, with the "market blank" with the original research in the sale of as of June 22, there are 79 inhalers (in the name of the drug and the declared enterprise name, excluding the evaluation) according to the new registration classification submitted to the listing application, involving 31 varieties (to active ingredients and dosage form) Ambromo sodo inhaling solutions are the most competitive, with a total of 10 pharmaceutical companies submitting listing or import applications under the new registration classification 31 existing enterprises to the new classification of the production of inhalers, 10 varieties of the current domestic market is temporarily in a blank state, China biopharmaceuticals, health yuan and other 11 pharmaceutical companies have been laid out; Figure 2: The number of declared varieties of 3 or more enterprises
from the declaration of enterprises, 8 pharmaceutical enterprises (in the group) have 3 and more inhalers to the new classification of production, four Trump-Trump specialty medicine, health yuan to 10 varieties of the lead, Hebei Renhe Yikang Pharmaceuticals with 5 varieties followed, China Biopharmaceuticals with 4 varieties ranked third 40 inhalers published reference preparations, these 11 have no enterprise layout
the State Drug Administration has announced 29 batches of generic drug-like reference preparation catalog, like injections, inhaler "figure" also appeared in the 21st batch of reference preparation sagents, so far 40 inhalers published reference preparations Minet data show that 40 published reference agents of 29 existing enterprises to submit a new classification of the application for listing, approved production will be treated as through the consistency evaluation, involving health yuan, Zhengda Qing, Hengrui and other more than 30 pharmaceutical enterprises Table 4: Inhaler Note that has been published and has not yet been evaluated for consistency of enterprise layout: Sales are less than 30 million symbols - representing 11 inhalers in the have not yet had the enterprise layout consistency evaluation, of which 7 inhaler original research products have been approved in China, 4 inhaling agent original research products have not yet entered the domestic market Budinefo Motero inhaled powder mist agent (I, II) in 2019 China's public medical institutions terminal sales of more than 2 billion yuan, currently only the original research manufacturer AstraZeneca products listed for sale, there is no enterprise layout consistency evaluation pento bromine powder inhaler has been approved for the market, in 2019 in China's public medical institutions terminal sales of more than 1 billion yuan, the current listed generic drugs have not yet submitted a consistency evaluation supplement application, there is no enterprise to the new registration classification of production .